Complement CH50 Test

Your immune system has a built-in chain reaction designed to punch holes in bacteria and clear debris from your bloodstream. This cascade, called the classical complement pathway, relies on nine proteins working in precise sequence. If even one is missing or depleted, the entire chain breaks. CH50 (total hemolytic complement, meaning it measures how well your blood can destroy target cells) is the only test that checks whether this whole sequence is intact and functional, not just whether individual proteins are floating around in your blood.

Most standard lab panels never test complement function. That means a person could carry a genetic gap in this defense system for years, suffering unexplained infections or autoimmune symptoms, without anyone checking the one test that would reveal the problem. CH50 fills that blind spot.

What CH50 Actually Measures

The complement system is a network of roughly 50 proteins that serve as your innate immune system's first responders. Three different triggers can activate it, but CH50 specifically tests the classical pathway, which is set off when antibodies latch onto bacteria or other foreign material. The test works by mixing your serum with sheep red blood cells coated in antibodies, then measuring how effectively your blood destroys them. The result reflects the combined activity of all nine classical pathway proteins (C1 through C9).

Most of these proteins are made by the liver, though immune cells called macrophages and monocytes (white blood cells that engulf and digest foreign material) also produce some of them locally at sites of infection or inflammation. This dual production system means CH50 reflects both your liver's synthetic capacity and whether your immune system is actively consuming complement proteins to fight something.

What a Low CH50 Tells You

A low result means one of two things: either your body is not making enough of one or more complement proteins (a genetic deficiency), or your body is using them up faster than it can replace them (consumption from active disease). The distinction matters enormously, and the degree of reduction is the first clue.

A CH50 of zero or close to zero almost always points to a genetic defect. One of the nine proteins in the chain is absent, so the cascade cannot complete. A reduced but nonzero result suggests your complement system is being activated and consumed, typically by immune complexes (clumps of antibodies bound to their targets) formed during autoimmune flares or chronic infections. Your body is making the proteins, but something is burning through them.

Recurrent Infections

The strongest disease link for low CH50 is susceptibility to certain bacterial infections. The final steps of the complement cascade (proteins C5 through C9) form what is called the membrane attack complex, a molecular drill that punctures bacterial cell walls. Without it, your body struggles to kill encapsulated bacteria (bacteria wrapped in a protective outer shell), particularly Neisseria meningitidis (the cause of bacterial meningitis) and Neisseria gonorrhoeae.

A genetic study of 212 patients with complement deficiencies confirmed that people missing terminal pathway proteins (C5 through C9) face a markedly elevated risk of recurrent Neisseria infections. If you have had two or more episodes of meningococcal disease, or a single episode at an unusual age, a missing complement protein is a leading explanation.

Autoimmune Disease

Defects in the early classical pathway proteins (C1q, C1r, C1s, C2, and C4) show up differently. Rather than recurrent infections, these deficiencies tend to produce lupus-like autoimmune symptoms. The reason: these proteins are responsible for clearing immune complexes (clumps of antibodies bound to their targets) and dead cells from circulation. When clearance fails, those complexes deposit in tissues and trigger chronic inflammation.

Systemic lupus erythematosus (SLE) is the most common autoimmune association. In active lupus, immune complex formation consumes complement proteins, driving CH50 down. Low complement (C3, C4, or CH50) is included in the formal classification criteria for lupus diagnosis. Serial CH50 tracking can help gauge whether a lupus flare is active or subsiding.

Heart Disease

The evidence linking CH50 to cardiovascular outcomes is limited to smaller studies, but the signal is suggestive. In a study of 263 newly diagnosed hypertension patients with heart failure, those with CH50 levels at or above 294.6 micrograms per milliliter had roughly 4.5 times the risk of poor outcomes compared to those with lower levels (hazard ratio 4.57). Elevated complement activity in this context likely reflects chronic inflammatory activation damaging blood vessel walls.

In 69 patients with lupus, CH50 correlated directly with carotid artery wall thickness, a surrogate marker for early atherosclerosis. Higher complement activity was associated with thicker artery walls even after adjusting for traditional cardiovascular risk factors. These findings are preliminary and come from specific disease populations, so they should not be over-interpreted for the general public.

Cancer Associations

Elevated CH50 has been observed in certain cancers. In a study of 928 patients with non-small cell lung cancer followed over 10 years, those with CH50 above 480.56 micromoles per liter had about 1.6 times the risk of cancer-related death (hazard ratio 1.59). A separate study of 200 cancer patients found that complement levels tracked with disease stage: levels rose with tumor progression and returned toward normal in patients who achieved remission.

These findings suggest that tumors may stimulate complement production as part of a broader inflammatory response. However, CH50 is not a cancer screening tool. These associations come from patients who already had diagnosed cancers, and the test lacks the specificity to distinguish cancer-related elevation from other causes of increased complement activity.

Infection Severity and Mortality

A Japanese retrospective study of 2,726 patients with infections found that those with low CH50 (below 30 U/mL) had significantly worse outcomes than those with normal levels (30 to 50 U/mL) or high levels (above 50 U/mL). Low CH50 was associated with higher rates of blood clotting problems (coagulopathy), organ failure, and death within 180 days. This makes clinical sense: when complement is consumed during a severe infection, it signals that the immune system is overwhelmed.

What a High CH50 Means

Elevated CH50 is less clinically significant than low levels. Because complement proteins are acute-phase reactants (proteins the liver ramps up during inflammation), CH50 can rise modestly during any inflammatory state. Specific associations include certain cancers (leukemia, non-Hodgkin lymphoma), ulcerative colitis, and liver conditions like primary biliary cholangitis where bile flow obstruction can raise both CH50 and C3.

In patients being treated for lupus or other autoimmune diseases, a rising CH50 is actually good news. It suggests the treatment is working and complement consumption is slowing down.

Reference Ranges

CH50 reference intervals vary significantly between laboratories because the test depends on the specific laboratory method (assay), reagents, and calibrators each lab uses. There is no single universal normal range. The most clinically useful thresholds are qualitative rather than numeric.

These ranges are drawn from published research and clinical laboratory guidance. Your lab may report results in different units (U/mL, CAE units, or others) with different cutpoints. Always compare your results within the same lab over time rather than treating any single threshold as absolute.

Age and Sex Differences

Complement activity is not static across your lifespan. A study of healthy Caucasian adults found that classical pathway activity increases with age, driven by rising levels of C1-inhibitor, C5, C8, and C9. Women showed lower alternative pathway activity than men, with lower C3 and properdin levels, though classical pathway activity was similar between sexes. In children, a study of 163 healthy subjects from birth through age 14 found no significant relationship between CH50 and age, and no differences by sex or race for CH50 specifically.

When Results Can Be Misleading

CH50 is one of the most handling-sensitive tests in clinical medicine. Complement proteins degrade rapidly at room temperature. If your blood sample sits too long before processing, or if it is not stored at the correct temperature (ideally minus 80 degrees Celsius), the result will be falsely low. This is probably the most common reason for an unexpected low CH50.

The type of blood collection tube also matters. Tubes containing thrombin and gel separators produce more complement activation during collection, which can distort functional results. Glass tubes or silica clot activator tubes without gel separators are recommended.

Acute illness is a major confounder. Any active infection, autoimmune flare, or recent major trauma can consume complement and push CH50 down temporarily. Multiple trauma causes a rapid and profound drop in CH50 within the first 24 hours, recovering only after about 5 days. If you were recently sick, injured, or had surgery, wait until you have fully recovered before testing to get a meaningful baseline.

A heterozygous deficiency (one working copy and one defective copy of a complement gene) may produce no change in CH50 at all. The test is relatively insensitive to partial deficiencies. A normal CH50 does not guarantee that every complement protein is at full capacity.

Tracking Your Trend

A single CH50 reading is a starting point, not an answer. The test's value grows substantially when you track it over time, especially if you have an autoimmune condition, a history of unusual infections, or a family member with a known complement deficiency. In lupus, serial measurements of CH50, C3, and C4 are standard practice for catching flares before they cause organ damage.

For someone establishing a preventive baseline, get your first reading when you are feeling well and have not had any acute illness in the preceding two weeks. If the result is normal, annual retesting is reasonable if you have risk factors. If it is abnormal, retest within 4 to 6 weeks to confirm, and add C3, C4, and AH50 to pinpoint where the problem lies. Comparing results from the same laboratory using the same assay method is essential, because CH50 values are not directly comparable across different labs.